Lupin launches new antibiotic tablet

Pharma Major Lupin today announced the launch of  Doxycycline Hyclate Tablet USP, 100 mg. The drug is used for the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.
 
The company had earlier received approval from the United States Food and Drug Administration (FDA) for the drug. 
 
"Doxycycline Hyclate Tablet USP, 100 mg is an AB rated generic equivalent of Pfizer Inc’s Vibra-Tabs®, 100 mg," the company said in a statement. 
 
According to market research firm IMS MAT , Doxycycline Hyclate Tablet USP, 100 mg has annual sales prospect of approximately $144 million in the US.
 
Lupin, a manufacturer of branded plus generic formulations, biotechnology products and APIs, earns 47% from its US business.
For the financial year ended March 31, 2017, Lupin’s Consolidated sales and Net profit stood at Rs 171,19.8 crore ($2.55 billion) and Rs 25,57.5 crore ($381 million), respectively. 
 
At 2.40 pm, the company's stock was trading at 923, up 0.50% over the previous day's close on the BSE.